當(dāng)前位置： 首頁 - 產(chǎn)品目錄 - 小分子抑制劑
Cabozantinib (XL184,BMS 907351,Cometriq?) 卡博替尼
| 貨號 | ICG1092 | 售價（元） | 1918 |
| 規(guī)格 | 5mg | CAS號 | 849217-68-1 |
- 產(chǎn)品簡介
- 相關(guān)產(chǎn)品
貨號
名稱
規(guī)格
價格
ICG1092-0005MG
Cabozantinib
5MG
1918
ICG1092-0010MG
Cabozantinib
10MG
3002
ICG1092-0050MG
Cabozantinib
50MG
8412
ICG1092-0100MG
Cabozantinib
100MG
16500
產(chǎn)品簡介：
Cabozantinib (XL184,BMS-907351) 是一種新型 MET 和 VEGFR2 抑制劑，可同時抑制轉(zhuǎn)移、血管生成和腫瘤生長[1]。其對 VEGFR2 和 c-Met 的 IC50 值分別為 0.035 nM 和 1.3 nM[2]。
Cabozantinib(XL184) 處理 MDA-MB-231 和 HCC70 細(xì)胞的 MAME 培養(yǎng)物（表達(dá) HGF 的成纖維細(xì)胞）具有細(xì)胞毒性并顯著減少多細(xì)胞侵襲性生長，即使在含有表達(dá) HGF 的成纖維細(xì)胞的培養(yǎng)物中也是如此[3]。 Cabozantinib 誘導(dǎo)的細(xì)胞應(yīng)激導(dǎo)致 DU-145 細(xì)胞系發(fā)生 ICD（一種特殊類型的細(xì)胞凋亡）[4]。據(jù)報道，卡博替尼可通過阻斷膀胱癌細(xì)胞中的 HGF-MET 信號通路來抑制 MMP-1 的表達(dá)[5]?？ú┨婺崽幚砗驟SCC細(xì)胞MMP-1顯著降低，這是卡博替尼處理后ESCC細(xì)胞遷移活性降低的原因[6]。
卡博替尼抑制腫瘤生長在嚙齒動物的人類腫瘤模型中呈劑量依賴性[1]。體內(nèi)藥效學(xué)研究表明，單次口服卡博替尼[7]后，TT 異種移植腫瘤中的 RET 得到顯著抑制。使用 CRC（結(jié)直腸癌）外植體模型，卡博替尼在體內(nèi)表現(xiàn)出優(yōu)異的抗腫瘤作用[8]。
產(chǎn)品性質(zhì)：
Cas No.:849217-68-1
別名:卡博替尼; XL184; BMS-907351
化學(xué)名: 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Canonical SMILES COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
分子式:C28H24FN3O5
分子量:501.51
溶解度:≥ 25.1mg/mL in DMSO
儲存條件:4°C, protect from light
注意事項：
為了您的安全和健康，請穿實驗服并戴一次性手套操作。
References:
[1]. Yakes F Michael,Chen Jason, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.[J]. Molecular cancer therapeutics,2011,10(12).
[2]. Weon-Kyoo You, Barbara Sennino, et al. VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer[J]. Microenvironment and Immunology,2011.
[3]. Sameni Mansoureh,Tovar Elizabeth A, et al. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.[J]. Clinical cancer research : an official journal of the American Association for Cancer Research,2016,22(4).
[4] Scirocchi Fabio,Napoletano Chiara,et al. Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib[J]. Frontiers in Oncology,2021,11.
[5] Shintani T, Kusuhara Y, et al. The involvement of hepatocyte growth factor-MET-matrix metalloproteinase 1 signaling in bladder cancer invasiveness and proliferation. Effect of the MET inhibitor, cabozantinib (XL184), on bladder cancer cells. Urology. (2017) 101:169.e7-13. doi: 10.1016/j.urology.2016.12.006.
[6] Pei-Wen Yang, Yu-Cheng Liu, et al. Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)[J]. Frontiers in Oncology, 2019.
[7] Bentzien Frauke,Zuzow Marcus, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.[J]. Thyroid : official journal of the American Thyroid Association,2013,23(12).
[8] Scott Aaron J,Arcaroli John J,et al. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.[J]. Molecular cancer therapeutics,2018,17(10).